Paolo Tarantino: Trastuzumab Emtansine vs. Second Topoisomerase I-Based ADC After Trastuzumab Deruxtecan

Paolo Tarantino, Research Fellow presso Dana-Farber Cancer Institute, posted on X:

“In our retrospective Flatiron data presented at SABCS24, Trastuzumab Emtansine did seem to outperform a second topo1 ADC after progression on prior T-DXd.”